Home | About Us | Archive | Documents | Campaigns & Issues | Links | Contact Us

      ¡Venceremos! We Will Win!

      Thousands in London, Madrid protest military intervention in Syria

      November 28, 2015 (Press TV)

      Some 5,000 people gathered Saturday in central London while holding placards that read "Don't bomb Syria", "Drop Cameron, not bombs" and "Don't add fuel to the fire."

      “David Cameron's incoherent proposals for action in Syria will do nothing to weaken ISIL but will instead inflame the civil war, deepen the misery of the Syrian people and increase the terrorist risk," said a Stop the War Coalition member during the protest.

      Addressing the British parliament on Thursday, UK Prime Minister David Cameron explained his plans for British fighter planes, already bombing the Takfiri terrorists in Iraq, to join France and the US in targeting Daesh positions in Syria.

      A parliamentary vote on the subject is set to be held next week, when a large number of politicians reluctant to commence Syria attacks are expected to change their minds over the recent Paris attacks.

      No to war

      In Spain, at least 5,000 people gathered in the capital to protest the government’s potential involvement in the conflict in Syria.

      Thousands of protesters gather in front of the Reina Sofia Museum in Madrid, Spain in protest to potential Spanish military intervention in Syria, November 28, 2015. (EPA)

      Following the protest, Spanish Prime Minister Mariano Rajoy announced that he would hold off on any decision related to the subject.

      "Decisions have to be well thought through, as in any aspect of life," said Rajoy, adding that Madrid was also discussing the matter with its allies.

      CELAC to support legally binding climate change agreement

      November 10, 2015 (Granma News)

      The Community of Latin American and Caribbean States (CELAC) will support the adoption of a legally binding and universal climate change agreement during the forthcoming Climate Change Conference (COP21), the organization noted in a statement published yesterday in Ecuador.

      In the document, disseminated by the Ministry of Foreign Relations and Human Mobility of Ecuador, currently the integrationist organization’s President pro tempore, CELAC gave details about its most recent meeting held in the country on November 6.

      Thanks to efforts by the Ecuadorian government, the goal of working to establish a common position looking toward the 21st UN Climate Change Conference, has been achieved, the report notes.

      The COP21 event will take place in Paris during the first two weeks of December. According to CELAC, there, nations must reach a universal and legally binding agreement able to effectively contribute to the battle against the threat of climate change; a phenomenon for which industrialized nations are largely responsible.

      Important advances in identifying some 20 possible aspects of the organization’s common position toward COP21 were made during the high level meeting. Common challenges facing 33 CELAC member nations in regards to mitigation and adaptation to climate change, access to financing, clean technologies and capacity building were also identified during the regional encounter.

      Problems relating to climate vulnerability, losses and damages, especially considering current and future threats of hurricanes, floods, droughts, retreating glaciers, rising sea levels and El Niño and La Niña phenomena, among others, were also addressed during the CELAC meeting.

      Syria and Cuba sign health cooperation November 19, 2015 (Granma News)

      The medication Vaxira to treat advanced large cell lung cancer, developed by Cuba’s Molecular Immunology Center, received the Prize for Creativity and Technological Innovation 2015, awarded by the Cuban Industrial Property Office (OCPI).

      Registered in Cuba since 2012 after being approved by the Center for State Control of Medicines, Equipment and Medical Devices (Cecmed), the product shows positive results in prolonging and improving the quality of patients’ lives, and has low toxicity levels resulting in less of the unpleasant side effects associated with other necessary therapeutic procedures.

      The safety of the product allows it to be administered over long periods of time through the primary healthcare system, and is also suitable for elderly people suffering from the disease.

      Vaxira is patented in 17 countries, while clinical trials are currently underway to assess its possible use in treating varieties of breast and ovarian cancer

      Back to Article Listing